The key objectives of the meeting are to:

- Examine the state of markers of disease modification across the disease continuum, with an emphasis on early disease stages (and how to optimize their definition), in AD and PD.
- Contextualize clinical meaningfulness across the disease continuum in AD and PD by incorporating the patient voice.
- Prioritize which drug development tools are needed to accelerate development of disease modifying treatments in partnership with industry and drug development experts.